en · de · es · pt
cardarine-notes.peptides6823.com › Topic › Identity And Pharmacological Classification — Complete Guide

Identity And Pharmacological Classification — Complete Guide

By Editorial Desk · published 2025-08-20 · last reviewed 2025-09-22 · Topic

This is a working overview of PPARδ agonist, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-09-22 and is reviewed periodically as new material appears.

Identity and Pharmacological Classification

Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.

PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.

Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.

Identity and Regulatory Status

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine at a glance

PropertyValueNotes
Chemical classPPARδ agonistNot an anabolic steroid.
Common synonymsGW501516, GW-1516Cardarine is an informal name.
AppearanceWhite to off-white powderTypical for research-grade solid.
Solubility classPoorly soluble in water; soluble in some organic solventsSuch as DMSO or ethanol in laboratory settings.
Typical storage temperatureCool, dry, protected from lightSpecific conditions vary by supplier and form.

Background and Research Context

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

Related pages on this site

Cardarine Identity and Mechanism

At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.

Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.

Background from the literature

=== Pharmacodynamics === Esmodafinil has about 3-fold lower affinity for the dopamine transporter (DAT) compared to armodafinil or modafinil (Ki = 780 nM, 2,500 nM, and 2,300 nM, respectively). It showed about 2-fold lower potency than armodafinil and about 1.5-fold higher potency than modafinil as a dopamine reuptake inhibitor (DRI) in vitro (IC50Tooltip half-maximal inhibitory concentration = 8,700 nM, 4,000 nM, and 13,000 nM, respectively). Both enantiomers of modafinil preferentially bind to the DAT in an inward facing conformation that is associated with atypical DRI profiles. Esmodafinil was about 1.4- to 1.5-fold more potent than modafinil or armodafinil in substituting for cocaine in rodents. Esmodafinil and armodafinil have been said to have approximately equipotent pharmacological effects but differing pharmacokinetics. Esmodafinil has been researched for the treatment of cocaine addiction. Like armodafinil, esmodafinil attenuates the effects of cocaine by occupying the dopamine transporter. While doing so, esmodafinil increases dopamine levels in the nucleus accumbens to a lesser extent than cocaine. However, the short elimination half-life of esmodafinil has been cited as reason to investigate armodafinil as a cocaine addiction treatment instead.

== Production and processing == Producing a biomaterial from raw silk generally proceeds through three stages: the fibroin is purified, dissolved into a workable solution, then shaped and stabilised into a final form. Cocoons are boiled in a mild alkaline solution, usually sodium carbonate, which removes the sericin. The degummed fibres are then dissolved, most often in concentrated lithium bromide, a salt concentrated enough to disrupt the hydrogen bonds holding the beta-sheet domains together. Dialysis against water removes the salt and leaves an aqueous fibroin solution, the common precursor for nearly everything that follows. A single solution yields a striking variety of forms. Dried as a thin layer on a surface, it produces films and coatings used in optics, in sensors and to modify the surfaces of implants. When the protein assembles into a soft, water-swollen network—a transition driven by changes in pH or temperature, by sonication or by an applied electric field—the result is a hydrogel. Freeze-drying, or casting the protein around salt crystals or gas bubbles, produces porous sponges and scaffolds whose interconnected pores allow cells to grow in three dimensions. Drawing the solution through a high electric field spins it into fine fibres, a technique known as electrospinning, which yields non-woven mats resembling the natural network surrounding cells. The same solution can also be formed into microspheres and nanoparticles for carrying and releasing drugs.

== History == As early as the 17th century, the Spanish used quinine from the bark of Cinchona trees to treat malaria after being shown the remedy from the Indigenous peoples of Peru, Bolivia, and Ecuador. In early 19th century India and other tropical posts of the British Empire, medicinal quinine was recommended to British officials and soldiers to prevent malaria, where it was mixed with soda and sugar to mask its bitter taste, creating tonic water. The first commercial tonic water was produced in 1858 when a new invention "An improved aerated liquid" known as Quinine Tonic Water was patented by the owner of Pitt & Co., Erasmus Bond and manufactured at their Wharf Road, City Road London factory. The mixed drink gin and tonic also originated in British colonial India, when the British mixed their medicinal quinine tonic with gin and other ingredients to make the bitter medicine more palatable. Soldiers in India were already given a gin ration, so the concoction was easy to make. In 1868, the first known record of a gin and tonic was in the Oriental Sporting Magazine and was described as a refreshing cocktail for spectators of horse racing, not as a medicine.

Sources: en.wikipedia.org

Reference notes

==== Fat repositioning ==== Fat repositioning involves mobilizing orbital fat and redistributing it along the infraorbital rim to improve contour irregularities. This technique is commonly used to smooth the transition between the lower eyelid and cheek and to address tear trough deformities.

=== Detection in body fluids === Diphenhydramine can be quantified in blood, plasma, or serum. Gas chromatography with mass spectrometry (GC-MS) can be used with electron ionization on full scan mode as a screening test. GC-MS or GC-NDP can be used for quantification. Rapid urine drug screens using immunoassays based on the principle of competitive binding may show false-positive methadone results for people having ingested diphenhydramine. Quantification can be used to monitor therapy, confirm a diagnosis of poisoning in people who are hospitalized, provide evidence in an impaired driving arrest, or assist in a death investigation.

13 November The story of the 1968 My Lai Massacre was revealed to the public by freelance American investigative reporter Seymour Hersh, who was contributing to the Dispatch News Service. The New York Times published a similar report at the same time.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine also known as?

Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.

Is cardarine a steroid?

No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.

Has cardarine been approved for human use?

No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.

Is cardarine a SARM?

No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.

Network